CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.
CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.
Location: Israel, Center District, Kfar Sava
Employees: 51-200
Total raised: $70.8M
Founded date: 2009
Investors 4
| Date | Name | Website |
| - | aMoon Fund | amoon.fund... |
| - | Elron Vent... | elronventu... |
| - | Elron Elec... | elron.com |
| - | Arkin Hold... | arkinholdi... |
Funding Rounds 7
| Date | Series | Amount | Investors |
| 16.07.2020 | - | $15M | - |
| 01.02.2018 | - | $2.5M | - |
| 08.05.2017 | - | $18.3M | aMoon Fund |
| 13.01.2016 | - | $15M | - |
| 29.10.2013 | - | $5M | - |
| 09.07.2012 | - | $10M | - |
| 01.02.2012 | - | $5M | - |
Mentions in press and media 19
| Date | Title | Description |
| 23.05.2024 | Renowned New York Orthopedic Surgeon Dr. Steven Struhl Adopts Revolutionary Joint Cartilage Regeneration Procedure | Shoulders and Knees Dr. Steven Struhl, a leading orthopedic surgeon in New York, has successfully performed a groundbreaking procedure using Cartiheal's Agili-C™ implant to regenerate articular cartilage, offering new hope for patients with... |
| 26.07.2023 | CartiHeal Announces First Commercial Implantation of Agili-C™ in the US | KFAR SABA, Israel, July 26, 2023 /PRNewswire/ -- CartiHeal Ltd., developer of implants for the treatment of cartilage and osteochondral defects in arthritic and non-arthritic knee-joints, today announced its first commercial implantation of... |
| 11.04.2022 | Paradigm, Andreessen Horowitz, and Union Square Ventures sued over alleged ‘rampant fraud’ on Uniswap exchange | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. The most successful crypto funds have taken a hands-on approach with the founders they work with.... |
| 30.03.2022 | FDA approves CartiHeal's Implant for the Treatment of Cartilage and Osteochondral Defects | Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the k... |
| 30.08.2021 | US orthobiologics firm to buy Israeli medical tech company CartiHeal | Bioventus, a leading US orthobiologics firm, will be acquiring Israeli company CartiHeal, a developer of cartilage implants, for an estimated $500 million. The American company, an investor in CartiHeal, announced on Monday that it was exer... |
| 03.08.2021 | CartiHeal Announces Pivotal Study Results Demonstrate Agili-C™ Superiority to Microfracture and Debridement for the Treatment of Cartilage and Osteochondral Defects USA - English USA - English USA - ... | |
| 03.08.2021 | CartiHeal Announces Pivotal Study Results Demonstrate Agili-C™ Superiority to Microfracture and Debridement for the Treatment of Cartilage and Osteochondral Defects | According to a Two-Year Randomized and Controlled Multinational IDE Study KFAR SABA, Israel, Aug. 3, 2021 /PRNewswire/ -- CartiHeal Ltd, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and no... |
| 12.10.2020 | CartiHeal Receives FDA "Breakthrough Device Designation" for the novel Agili-C Implant USA - English USA - English | |
| 16.07.2020 | CartiHeal Raises $15M in Equity Funding from Bioventus | CartiHeal, the Kfar Saba, Israel-based developer of the proprietary Agili™-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints, secured an additional $15m equity investment from Bioventus, a global le... |
| 01.02.2018 | CartiHeal Secures $2.5M in Funding | CartiHeal, a Kfar Saba, Israel-based developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints, secured $2.5M in funding. Bioventus made the investment, which complements ... |
Show more